Are Weight Loss Injections Available on the NHS? UK Eligibility Explained

Quick Answer

Yes, some people can receive weight loss injections through the NHS, following assessment. In England, Mounjaro access includes specialist services and a phased primary-care rollout. NHS England's current patient information describes primary-care assessment for people with four qualifying weight-related conditions and a BMI of at least 35, adjusted for ethnicity. Wegovy's weight-management and cardiovascular recommendations have different criteria. Local pathways and clinical suitability still matter. Private assessment is a separate option, but meeting a BMI threshold or completing a consultation does not guarantee a prescription.

Phased accessMounjaro primary-care access prioritises clinical need

Local pathwaysAsk your GP or ICB which assessment route is operating

Individual assessmentNHS and private treatment both require a prescribing decision

Last updated: 19 October 2026

NHS weight loss injections criteria depend on the medicine, your health and the service available locally. Mounjaro (tirzepatide) and Wegovy (semaglutide) have NHS recommendations, but a medicine's licence, NICE funding guidance and access to an assessment are separate checks. This guide explains the routes in England, how private prescribing differs and what to ask while waiting. Scotland, Wales and Northern Ireland have their own arrangements; ask your local healthcare team about the pathway where you live. Understanding how weight loss injections work can help you prepare for that discussion.

NHS weight loss injections criteria and access routes

A referral, an assessment, a prescribing decision and medicine supply are separate stages. Being on a waiting list does not confirm that a particular medicine will be offered. The following routes describe England; national recommendations do not tell you the current waiting time or capacity of your own service.

Mounjaro: phased primary-care access

Primary-care access to tirzepatide is being introduced in stages. NHS England's patient information, checked on 19 October 2026, describes people with four qualifying weight-related health conditions and a BMI of at least 35, adjusted for ethnicity. This replaces the guide's older presentation of BMI 40 as the only current threshold. Ask your GP or integrated care board (ICB) which cohort and assessment service are operating locally.

Framework	Criteria or purpose	What to check
NICE TA1026	Initial BMI of at least 35 and at least one weight-related condition; lower BMI thresholds apply for specified ethnic backgrounds	This broader recommendation is different from the phased primary-care access rules
Primary care in England	Current patient information describes four qualifying conditions and BMI of at least 35, adjusted for ethnicity	Confirm the current local cohort and referral process with your GP or ICB
Specialist services	Assessment through a specialist weight-management pathway, applying the relevant medicine's criteria	Ask whether your referral has been accepted and what treatment and support the service offers

The five qualifying conditions used for primary-care prioritisation are type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. Four of these are required under the current patient information. A clinician must check your diagnoses and BMI; this list is not a self-prescribing checklist. People prescribed tirzepatide through primary care should also receive dietary and physical-activity support.

Specialist weight-management services

Specialist teams provide assessment and multidisciplinary support. Mounjaro's NICE weight-management recommendation uses an initial BMI of at least 35 with at least one weight-related condition. The BMI threshold is usually reduced by 2.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. Access and prioritisation depend on the service and current commissioning arrangements.

For Wegovy weight management, NICE TA875 recommends treatment within a specialist service for a maximum of two years, with at least one weight-related condition and a BMI of at least 35, or 30 to 34.9 where specialist-referral criteria are met. Lower BMI thresholds apply for specified ethnic backgrounds. Do not apply one medicine's criteria to every injection.

Waiting times vary by area, referral stage and service capacity. There is no single national waiting time that predicts your appointment. Ask the service for its current estimate, what support is available while waiting and how to report a change in your health.

Wegovy for cardiovascular risk reduction

NICE TA1152, published on 7 May 2026, is a separate recommendation for semaglutide alongside a reduced-calorie diet and increased activity in adults with established cardiovascular disease and a BMI of at least 27. It covers up to a maintenance dose of 2.4 mg once weekly. The defined cardiovascular history includes a previous heart attack, previous stroke or specified symptomatic peripheral arterial disease. A TIA alone is not included in that definition.

This is not a general lower-BMI weight-loss pathway. NICE says the treatment must be funded in England for the recommended population when it is the most suitable option, within 90 days of final guidance. It does not specify the prescribing setting. The recommendation therefore should not be described as automatic GP prescribing or a guaranteed way to bypass a referral.

Ask about the right pathway

If you have established cardiovascular disease, ask your usual clinician whether this recommendation applies and which local service can assess you. Do not assume that a qualifying BMI alone, or any previous cardiovascular symptom, establishes eligibility.

NHS vs private: eligibility, cost and assessment

The NHS funding criteria can be narrower than a medicine's licensed indication. Private prescribing is a separate clinical decision and is not a way to move ahead in an NHS queue. Compare the assessment process and the ongoing care you can realistically afford.

Route	Eligibility framework	Timing and cost
NHS Mounjaro primary care	Phased priority cohorts; current patient information describes BMI 35+ and four qualifying conditions, adjusted for ethnicity	Local assessment capacity and pathway apply; meeting criteria does not mean immediate supply
NHS specialist weight management	Medicine-specific NICE criteria and referral assessment	Waiting times vary; ask your own service for an estimate
NHS semaglutide cardiovascular prevention	BMI 27+ and established cardiovascular disease as defined in TA1152	Ask which local service assesses and prescribes; no setting is specified by NICE
Private adult weight management	For Mounjaro and Wegovy, the licensed indication includes BMI 30+, or 27 to below 30 with a weight-related condition	Individual assessment and an ongoing treatment budget are required; approval and delivery are not guaranteed

If you are considering Mounjaro privately, compare the full treatment cost and assessment process before you buy Mounjaro online. A prescriber must confirm whether treatment is suitable for you.

You can check your BMI and private treatment eligibility before starting an assessment. The calculator is a guide, not confirmation of NHS access or a prescription.

Compare the full treatment budget

A starting price is only one part of the cost. Compare the prescribed dose, pack duration, purchase option, delivery charges and included follow-up. Ask how repeat prescriptions are reviewed and check any subscription and cancellation terms. A first-order promotion does not establish the cost of several months of care.

The prescriber decides the dose and schedule. Do not rush dose increases, change treatment or restart after a break to reduce costs. If continuing becomes difficult to afford, speak to the prescribing team before your next supply is due. Private treatment should not put essential household spending at risk.

Why NHS access is phased

NICE estimated that around 3.4 million adults in England could meet its broader tirzepatide recommendation, while the implementation plan expected at least 220,000 people to be eligible for funded treatment within the first three years. These are planning estimates, not promises of prescriptions or an individual waiting time. Phased access prioritises clinical need while services develop capacity.

Primary-care tirzepatide treatment includes wraparound support for nutrition and activity. Medicine, dietary changes, suitable physical activity and regular review form a treatment plan together. The availability of medication does not remove the need for support or make it suitable for everyone.

Which medicines are covered?

Medicine	NHS weight-management route	Other considerations
Mounjaro injection (tirzepatide)	Specialist services and phased primary care under TA1026	Private prescribing uses an individual clinical assessment
Wegovy injection (semaglutide)	Specialist weight management under TA875	A separate cardiovascular recommendation, TA1152, has different criteria and does not specify a prescribing setting
Wegovy tablets (oral semaglutide)	Do not assume the injection recommendations cover tablets	The MHRA authorised the weight-management tablet on 11 June 2026; check the current formulation-specific NHS pathway
Saxenda injection (liraglutide)	NICE TA664 describes a specialist-service route for a defined group	Its criteria and supply arrangements differ from Mounjaro and Wegovy

Licensing and NHS funding are different decisions. The oral Wegovy authorisation does not, by itself, establish NHS availability. A prescriber should explain the exact medicine, formulation and indication being considered. Do not switch between tablets and injections or combine weight-loss medicines yourself.

What to do while waiting for NHS assessment

Find out whether you are waiting for referral acceptance, an initial appointment, a prescribing decision or supply. Keep the service name, referral date and contact details. Ask for an estimate for your own stage of care rather than relying on a general waiting-time claim.

Check that the service has received your referral and any information it needs.
Ask what dietary, activity or weight-management support is available before the appointment.
Find out how to report changes in health, medicines, contact details or circumstances.
Contact the referring team if you have not heard back within the timeframe it gave you.

New symptoms need appropriate clinical advice and should not simply wait for a future weight-management appointment. Continue existing prescribed medicines unless your clinician advises otherwise. A national rollout lasting several years does not mean you personally must wait that whole period.

Considering private treatment safely

A private consultation should review accurate height and weight measurements, health conditions, current medicines, previous treatment and side effects. If you have used a weight-loss medicine before, give its name, dose, dates and details of any break. An online form being available at any hour does not mean approval, clinical support or delivery is available around the clock.

Happy Pharmacy's published process includes review by a UK healthcare professional and further information or a video consultation when required. Supply follows a prescribing decision and dispensing. Ask for current response and delivery estimates; further checks, weekends and bank holidays can affect timing.

If you start privately while an NHS referral remains active, tell both teams and avoid duplicate prescriptions. Do not assume the NHS will automatically take over the same medicine, dose or cost later. Ask the NHS service about its own assessment and transfer policy.

Important

Check that an online pharmacy is registered with the GPhC, including the website and address. Avoid sellers offering prescription medicines through informal social-media or messaging channels without an appropriate assessment. Read the supplied patient leaflet. Severe or persistent abdominal pain, particularly spreading to the back, needs urgent medical attention; tell the clinician which medicine you use.

Expectations and follow-up

Weight loss and tolerability vary. A trial average or another person's result is not a promise of a fixed weekly or first-month loss. Discuss progress and side effects with your prescriber, and know how to contact the team between prescriptions. Do not change a dose, share a pen, combine medicines or restart after a break without prescribing advice.

Frequently asked questions

Can I get Mounjaro on the NHS?

Possibly, after assessment. In England, access includes specialist services and phased primary care. Current NHS England patient information describes primary-care access for people with four qualifying conditions and BMI of at least 35, adjusted for ethnicity. Ask your GP or ICB about the current local cohort and pathway. Meeting criteria does not guarantee a prescription.

Can I get Wegovy on the NHS?

Wegovy has a specialist weight-management recommendation under TA875 and a separate cardiovascular risk-reduction recommendation under TA1152. The latter covers a defined established cardiovascular history and BMI of at least 27; it does not specify a prescribing setting. Ask which pathway applies to your circumstances.

Is the Wegovy pill available on the NHS?

The MHRA authorised oral Wegovy for weight management on 11 June 2026. That authorisation alone does not establish NHS access. Do not assume guidance for injections covers tablets; ask your clinician or local NHS service about the current formulation-specific funding and pathway.

What's the difference between a licence, NICE guidance and local access?

A licence describes an authorised use. NICE evaluates whether a treatment should be an NHS-funded option for a defined group. Local services arrange assessment and prescribing, with phased implementation applying to some treatments. Your individual clinical suitability must still be assessed.

Why are NHS criteria different from private criteria?

The licensed indication can be broader than the population recommended for NHS funding or prioritised in a phased rollout. Private clinicians still assess suitability, medical history and risks. Meeting a BMI threshold is not an entitlement to treatment through either route.

Do I need a GP referral for private treatment?

You can request a private assessment directly through Happy Pharmacy. Provide accurate health and medicine information and keep your usual healthcare team informed. Further information or a video consultation may be required. Treatment is supplied only if the prescriber approves it.

How long is the NHS waiting list?

There is no single waiting time that applies to everyone. It depends on your local service, the stage of the referral and capacity. Ask the service holding your referral for its current estimate and what support is available while waiting.

What are the five qualifying conditions for primary-care Mounjaro?

Type 2 diabetes, high blood pressure, dyslipidaemia, obstructive sleep apnoea and cardiovascular disease. Current NHS England patient information describes four of these together with BMI of at least 35, adjusted for ethnicity. Your clinician should confirm diagnoses and the current local pathway.

Can I request private treatment while waiting for NHS care?

Yes, you can request an independent assessment, but it does not guarantee a prescription or change your NHS waiting-list position. Tell both teams if treatment begins and avoid duplicate prescribing. Future NHS continuation is not automatic.

What if I cannot afford to continue private treatment?

Contact your prescribing team before the next supply is due so you can discuss a safe plan. Do not change doses or ration treatment yourself. Check ongoing costs, review arrangements and subscription terms before committing.

Is private treatment automatically as safe as NHS treatment?

Safety depends on appropriate assessment, legitimate supply, individual suitability and follow-up. Licensed medicine from a regulated provider is important, but the medicine alone does not establish the quality of the whole service. Check registration, clinical checks and how to obtain advice about side effects.

Will eligibility change again?

Access arrangements can change as services and phased rollout develop. The information in this guide was checked on 19 October 2026. Confirm current arrangements with your healthcare team, especially if an older article or local leaflet gives different criteria.

Our weight loss medications overview explains the options discussed by Happy Pharmacy. Suitability is assessed individually.

Request a private weight-loss assessment

If you would like to explore private treatment, complete the consultation with accurate information about your health, medicines and treatment history. Our prescribing team will assess whether an option is suitable; requesting a consultation does not guarantee approval.

Start Your Free Online Consultation →

Compare ongoing costs and understand the review arrangements before committing to treatment.

Happy Pharmacy is a GPhC-registered pharmacy (No. 9013192). Superintendent Pharmacist: Palvinder Deol.

References

Access and service information checked 19 October 2026. Local pathways and service estimates can change.

Medically Reviewed by Our GPhC-Registered Pharmacists

Authored by:

Palvinder Deol
Superintendent Pharmacist
Over 25 years' clinical experience.

GPhC: 2047066 LinkedIn

Reviewed by:

Nigel Howard
Independent Prescriber
Over 20 years' clinical experience.

GPhC: 2047450

Your cart is currently empty.